Heron Therapeutics, Inc.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.
Find out what a historical investment in Heron Therapeutics, Inc. would be worth today using our HRTX stock calculator.
$152.81M
-
0.00%
1.23M
$0.81
$0.76
$0.81
$2.61
$0.74
Ready to start your investing journey with Stake?
Open an accountHRTX FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in HRTX
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in HRTX
on Stake
Buy HRTX from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of HRTX from only US$10 with fractional shares
